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Abstract
Background: Chronic intermittent hypoxia, platelet activation and inflammation all play roles in the pathogenesis of
obstructive sleep apnea syndrome (OSAS), which may increase the risk of cardiovascular disease (CVD). The aim of this
study was to evaluate the relationship of the platelet-to-lymphocyte ratio (PLR) as a new biomarker showing systemic
inflammation and platelet distribution width (PDW) as an indicator of platelet activation to the severity of OSAS.
Methods: A total of 290 patients suspected with OSAS who underwent a full night of polysomnography were
included. The patients were placed into 4 separate groups according to their apnea-hypopnea index (AHI) scores; the
control group (AHI <5), mild OSAS group (AHI 5–15), moderate OSAS group (AHI 16–30), and severe OSAS group
(AHI >30). CVD risk was defined by the presence of hypertension, diabetes mellitus, current smoking, and dyslipidemia.
Results: Higher AHI groups were significantly correlated with increasing age, body mass index, systolic blood pressure
and male sex. PLR and PDW were also significantly associated with AHI (r = 0.417 for PLR and r = 0.227 for PDW, all
p-values < 0.001) and the Epworth sleepiness scale (r = 0.160 for PLR and r = 0.189 for PDW, all p-values <0.05).
Multivariate regression analysis revealed that AHI ≥9.2 (adjusted odds ratios [OR] 5.03, 95 % confidential interval
(CI) = 1.67-15.2, p = 0.004) and PLR ≥159 (adjusted OR 2.81, 95 % CI = 1.34-5.91, p = 0.006) were independently
associated with the presence of hypertension.
Conclusion: PLR and PDW are associated with OSAS severity. PLR may also be useful as a systemic biomarker for the
concurrent hypertension in OSAS patients.
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Background
Obstructive sleep apnea (OSA) induces hypoxia and hyper-
capnia, which adversely affect the myocardial oxygen
supply. These changes ultimately contribute to the develop-
ment of altered metabolic, immune, and inflammatory
systemic responses [1]. Several studies have previously
demonstrated that obstructive sleep apnea syndrome
(OSAS) is an independent risk factor for cardiovascular
morbidity and mortality [2, 3] including coronary artery
disease and stroke [4, 5]. There is some evidence suggesting
that OSAS is associated with low-levels of systemic
inflammation and oxidative stress [1]. This chronic inflam-
mation in OSAS may play an important role in the progres-
sion of atherosclerosis and cardiovascular disease (CVD)
[6–9]. Therefore, it is important to clarify the association
between inflammation and disease severity in order to de-
termine the influence of OSAS on CVD.
Increased platelet activation plays a major role in the
initiation and progression of atherosclerosis [10]. Recent
studies have also introduced a new inflammatory marker,
the platelet-to-lymphocyte ratio (PLR), which can predict
adverse outcomes in CVD [11, 12]. Furthermore, interac-
tions between platelets, leukocytes and endothelial cells
during the inflammatory cascade may promote athero-
sclerotic changes [12–14]. During an inflammatory
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response, there is an increase in the platelet number and
platelet swelling, both of which may affect the platelet dis-
tribution width (PDW) [15, 16]. The PLR and PDW are
both relatively easy to measure as routine laboratory bio-
markers of systemic inflammation. However, there is little
data regarding their usefulness in patients with OSAS.
Therefore, the aim of this study was to evaluate the rela-
tionship between PLR, PDW and OSAS severity, as
assessed by polysomnographic parameters. In addition, we
investigated the role of PLR in hypertension, and the asso-
ciation between PLR and AHI severity.
Methods
Patient selection
This is a retrospective cohort study performed at two
centers. A total of 290 patients who had undergone
polysomnography between January 2010 and December
2014 were evaluated. Patients were considered for inclu-
sion if they were between 18 and 80 years old, had nor-
mal renal function and regular menstruation (with
regard to the women included). Patients were excluded
if any of the following criteria applied: systemic disease
such as liver disease; neurologic disorders or malignancy;
secondary hypertension; respiratory infection and failure;
critical illness with poor functional status; refractory
arrhythmia; history of heart failure; history of acute
coronary syndrome, myocardial infarction and/or any re-
vascularization procedure. Demographic characteristics
including age, sex, height, weight, current medications,
smoking history and other diseases were recorded at first
visit. Patients were assessed for any CVD risk factors in-
cluding the presence or absence of medically diagnosed
Table 1 Baseline patient characteristics
Control (n = 61) Mild OSAS (n = 67) Moderate OSAS (n = 61) Severe OSAS (n = 101) ANOVA p
Age, years 44.0 ± 15.4 48.2 ± 13.4 49.1 ± 11.8 51.4 ± 12.5* 0.003
Male, n (%) 33 (54.1) 39 (58.2) 41 (67.2)* 80 (79.2)* <0.001
BMI, kg/m2 24.2 ± 4.43 24.7 ± 3.20 26.4 ± 3.58*,+ 26.9 ± 3.41*,+ <0.001
SBP, mmHg 123.4 ± 13.7 123.5 ± 13.1 128.5 ± 13.6* 128.2 ± 12.4* 0.027
DBP, mmHg 78.4 ± 10.7 77.0 ± 8.9 80.8 ± 9.2 81.2 ± 9.9* 0.039
Heart rate, /min 72.6 ± 7.90 73.3 ± 10.3 76.3 ± 10.5 76.7 ± 9.15* 0.020
Hypertension, n (%) 5 (8.2) 13 (19.4) 18 (29.5)* 30 (29.7)* 0.005
Diabetes mellitus, n (%) 1 (1.6) 2 (3.0) 4 (6.6) 13 (12.9) * 0.048
Dyslipidemia, n (%) 2 (3.3) 2 (3.0) 3 (4.9) 3 (3.0) 0.917
Smoking, n (%) 6 (9.8) 14 (20.9) 12 (19.7) 18 (17.8) 0.123
Total cholesterol, mg/dl 170.0 ± 38.2 184.0 ± 34.6 190.6 ± 45.6 172.4 ± 46.9 0.161
TG, mg/dl 141.1 ± 84.8 151.2 ± 8.03 160.8 ± 89.1 176.1 ± 144.9 0.606
FBS, mg/dl 101.5 ± 17.2 92.8 ± 10.3 105.8 ± 21.7 111.6 ± 45.3 0.034
ESR, mm/hr 7.8 ± 11.6 17.9 ± 30.2 15.5 ± 15.3 14.0 ± 10.9 0.224
hs-CRP, mg/L 0.53 ± 1.32 1.14 ± 2.28 0.82 ± 1.38 1.12 ± 2.08 0.529
WBC, x106/L 6759 ± 1806 7283 ± 2031 7314 ± 2976 7724 ± 2051 0.103
Neutrophil, % 53.1 ± 11.2 59.1 ± 11.0 55.1 ± 13.8 60.5 ± 10.3* 0.001
Lymphocyte, % 36.1 ± 9.87 33.0 ± 12.8 30.0 ± 9.22 27.4 ± 8.35* <0.001
Eosinophil, % 2.24 ± 1.66 3.01 ± 2.03 2.60 ± 1.99 2.90 ± 2.16 0.217
Monocyte, % 7.91 ± 2.54 7.44 ± 2.15 8.51 ± 5.96 7.35 ± 1.71 0.234
RBC, x109/L 4587 ± 423.9 4692 ± 377.2 4660 ± 282.4 4599 ± 378.1 0.286
Hemoglobin, g/dl 13.5 ± 1.5 14.0 ± 1.4 13.8 ± 1.6 14.4 ± 1.6* 0.004
Hematocrit, % 40.2 ± 4.4 41.2 ± 4.2 40.2 ± 6.6 42.5 ± 4.5* 0.010
RDW, % 13.5 ± 1.57 13.3 ± 1.25 13.5 ± 1.05 13.3 ± 0.76 0.735
Platelet, x109/L 216.7 ± 54.4 224.8 ± 56.0 231.3 ± 80.6 252.4 ± 66.8* 0.007
PLR 99.5 ± 42.1 113.8 ± 45.2 121.3 ± 62.9* 138.6 ± 59.9* 0.001
PDW, % 15.9 ± 1.12 16.3 ± 0.95 16.4 ± 0.99* 16.5 ± 0.82* 0.003
All values are presented as means ± SD. BP, blood pressure; hs-CRP, high sensitivity C-reactive protein; OSAS: obstructive sleep apnea syndrome; BMI, body mass
index; SBP, systolic blood pressure; DBP, diastolic blood pressure; TG, triglyceride; FBS, fasting blood sugar; ESR, erythrocyte sedimentation rate; WBC, white blood
cell; RBC, white blood cell; RDW, red cell distribution width; PLR, platelet lymphocyte ratio; PDW, platelet volume distribution width, *p < 0.05 vs. control group,
+p < 0.05 vs. mild OSAS group
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hypertension, diabetes mellitus, dyslipidemia, and current
smoking status. Blood pressure (BP) was measured with
using a standard mercury manometer. Hypertension was
defined as systolic BP (SBP) ≥140 mmHg, diastolic BP
(DBP) ≥90 mmHg and/or current use of antihypertensive
drugs. Body mass index (BMI) was calculated as the ratio
of dry weight in kilograms to height in meters squared. This
study was approved by the Institutional Review Board.
Polysomnography
The full night polysomnography (PSG) studies used for
OSAS diagnosis were retrospectively reviewed. Full night
PSG (Embla N7000, Broomfield CO, USA) examination
was performed using a device equipped with a snoring sen-
sor, respiratory effort sensors, pressure sensor, body pos-
ition center, thermister, electroencephalography (EEG),
electrocardiogram (ECG), pulse oximeter with oxygen sat-
uration, lower extremity electromyography and chest ex-
cursion. The value index of PSG testing included AHI
scores, percentage of sleep efficacy, total sleep time, base-
line/lowest oxygen saturation, and the Epworth sleepiness
scale (ESS). The ESS was evaluated before PSG using a sur-
vey. Apnea was defined as a standstill in the airflow for
more than 10 s. Hypopnea was defined as ≥30 % reduction
in airway flow for more than 10 s followed by a decrease of
approximately 4 % in the patient’s oxygen saturation [17].
AHI was used as an index to represent the severity of ob-
structive sleep apnea. It is defined as the average frequency
of apnea and hypopnea events per hour during sleep. The
subjects were distributed into four groups according to
their AHI scores: the control group with AHI <5, mild
OSAS group with AHI 5–15, moderate OSAS group with
AHI 16–30, and severe OSAS group with AHI score >30.
Laboratory measurements
The biochemical parameters analyzed included total
cholesterol, triglyceride, fasting glucose, erythrocyte
sedimentation rate (ESR), high sensitivity C-reactive
protein (hs-CRP), and complete blood cell count. The
PLR was calculated by dividing the lymphocyte from
the platelet.
Statistical analyses
Statistical analyses were performed using the commer-
cially available computer program SPSS 18.0 for Windows
(SPSS Inc., Chicago, IL, USA). Data are presented as
means ± standard deviations for continuous variables and
their percentages (%) for categorical data. The Mann -
Whitney U test was used for continuous variables and the
chi-square test was used for categorical data. The
Kolmogorov-Smirnov test was used to test the data’s nor-
mality. Parameter differences among the three groups
were evaluated using a one-way analysis of variance
(ANOVA) or the Kruskal–Wallis test for normally or non-
normally distributed variables, respectively. The Tukey
test was used for multiple comparisons. Pearson cor-
relation coefficients were used to determine relation-
ships between variables. Linear association analysis
was used to verify the correlations between variables.
Receiver operator characteristic (ROC) curve analysis
was used to estimate the cutoff values for AHI and
PLR in the prediction of hypertension. Multivariate logis-
tic regression models were built to determine which vari-
ables are independently associated with concurrent
hypertension. Two-tailed p-values < 0.05 were considered
statistically significant.
Fig. 1 The prevalences of hypertension and diabetes mellitus were significantly higher in the moderate/severe OSAS group than they were in
the control group
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Results
There was a total 290 patients including 193 men
(66.6 %) and 97 women (33.4 %) included in this study.
The mean age was 48.6 ± 13.4 years (range: 18–78).
There were 61 control patients, 67 mild OSAS, 61 mod-
erate OSAS, and 101 severe OSAS patients. Table 1
shows the baseline clinical and laboratory characteristics
of each group. In general, the OSAS groups had older
patients with significantly more men than did the con-
trol group. In addition, the BMI, SBP, heart rate, and
fasting blood glucose were higher in the OSAS groups
than the control group. Age, BMI, and male proportion
increased significantly with increasing AHI. The preva-
lence of hypertension or diabetes mellitus was signifi-
cantly higher in the moderate/severe OSAS group than
they were in the control group (all p-values < 0.05, Fig. 1).
In addition, as the OSAS severity increased, there were
significant gradual increases in PLR (controls: 99.5 ±
42.1, mild OSAS; 113.8 ± 45.2, moderate OSAS; 121.3 ±
62.9 and severe OSAS; 138.6 ± 59.9, p = 0.001, Fig. 2a)
and in PDW (controls: 15.9 ± 1.12, mild OSAS; 16.3 ±
0.95, moderate OSAS; 16.4 ± 0.99 and severe OSAS;
16.5 ± 0.82, p = 0.003). Table 2 shows the polysomnogra-
phy data among the 4 groups. With increasing AHI,
Fig. 2 The relationship between platelet-to-lymphocyte ratio (PLR) and the clinical features of obstructive sleep apnea syndrome (OSAS). a There
were gradual but significant increases in the PLR (controls: 99.5 ± 42.1, mild OSAS; 113.8 ± 45.2, moderate OSAS; 121.3 ± 62.9 and severe OSAS;
138.6 ± 59.9, p = 0.001). b The PLR was most significantly elevated in OSAS patients with hypertension compared to those without and to controls
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there were significant stepwise decreases in the total
sleep time and the saturation value, and significant in-
crease in ESS. As expected, there were significant differ-
ences between the AHI groups with regard to the pre
ESS score, baseline saturation and lowest saturation (all
p-values <0.05).
Then, we analyzed the correlations between inflamma-
tory markers and the clinical OSAS factors. PLR was sig-
nificantly associated with AHI (r = 0.417, p <0.001, Fig. 3a),
minimum O2 saturation values (r = −0.192, p = 0.005), ESS
(r = 0.160, p = 0.047) and hs-CRP (r = 0.367, p < 0.001).
In addition, PDW was significantly correlated with
AHI (r = 0.227, p <0.001, Fig. 3b), minimum O2 satur-
ation values (r = −0.165, p = 0.011) and ESS (r = 0.189,
p = 0.018). However, red blood cell count (RBC) showed
no significant correlation with AHI (r = −0.103, p = 0.081).
Multivariate logistic regression analysis showed that PLR
(beta = 0.358, p <0.001) and PDW (beta = 0.186, p = 0.002)
were independently associated with AHI after adjustment
of the presence of hypertension, diabetes mellitus, dyslip-
idemia, obesity defined as BMI ≥ 25 kg/m2 and current
smoking status.
In sub-group analysis, OSAS patients with hyperten-
sion were found to have significantly higher AHI, ESS,
PLR and PDW values than do those without hyperten-
sion (Table 3). Among these parameters, PLR and AHI
were most significantly elevated in OSAS patients with
hypertension compared to those without and to controls
(Fig. 2b, Table 3). Furthermore, hypertension was signifi-
cantly associated with AHI ≥9.2 (ROC area under curve:
0.66, 95 % confidence interval (CI) = 0.60–0.71, p < 0.001)
and PLR ≥159 (ROC area under curve: 0.66, 95 % CI =
0.59–0.72, p < 0.001). Multivariate logistic regression
analysis showed that AHI ≥9.2 (adjusted odds ratios
[OR] 5.03, 95 % CI 1.67-15.2, p = 0.004) and PLR ≥159
(adjusted OR 2.81, 95 % CI = 1.34-5.91, p = 0.006)
were independently associated with the concurrent
hypertension in OSAS after adjusting for age, male
gender, and BMI (Table 4).
Discussion
In the present study, we showed that the indicator of
platelet activation (PDW) and systemic inflammation
(PLR) were both found to be significantly associated
with OSAS severity (reflected by AHI). In addition, we
have demonstrated that PLR may be a systemic bio-
marker that is independently associated with concurrent
hypertension in OSAS patients. OSAS is a chronic dis-
ease that is frequently associated with various comorbid-
ities including cognitive impairment, CVD, pulmonary
disease, endocrine dysfunction, and neuropsychiatric
problems [18–20]. The exact mechanism of OSAS and
its subsequent comorbidities is not known. However,
chronic systemic inflammation has been proposed in
several recent studies as a possible mechanism [21–23].
Although the inflammation plays an important role in
the progression and destabilization of atherosclerosis
and CVD [24, 25], it is unclear if this it is the cause
or result of OSAS. There have been conflicting reports on
the relationship between inflammatory markers and the de-
gree of the upper airway obstruction [26, 27]. Korkmaz M.
et al. [26] showed that the traditional inflammatory markers
such as CRP and ESR cannot predict the severity of the
level of systemic inflammation in OSAS patients. Because
systemic inflammation and resultant vascular insult is an
important underlying mechanism in OSAS, exploring new
inflammatory markers in OSAS may offer more informa-
tion in order to predict the risk of associated diseases.
The PLR combines the predictive risk of platelet and
lymphocyte counts into a new prognostic marker of in-
flammation for many types of cardiovascular disease in-
cluding hypertension, coronary artery disease, occlusive
peripheral arterial disease [11, 12], and atherosclerosis
[28]. Elevated platelet counts reflect underlying inflamma-
tory states, because platelets are acute phase reactants that
are produced in response to various stimuli including sys-
temic infections, inflammatory conditions, bleeding, and
tumors. Low levels of lymphocytes represent an uncon-
trolled inflammatory pathway. Therefore, an elevated PLR
Table 2 Group comparison according to polysomnographic parameters
Control (n = 61) Mild OSAS (n = 67) Moderate OSAS (n = 61) Severe OSAS (n = 101) ANOVA p
AHI 1.91 ± 1.69 9.14 ± 3.03* 21.5 ± 4.98*,+ 72.5 ± 51.7*,+ <0.001
Sleep efficiency, % 81.0 ± 9.14 81.0 ± 9.91 82.0 ± 10.3 77.1 ± 13.1* 0.026
Total sleep time, min 322.8 ± 44.8 298.7 ± 60.4 292.2 ± 62.4 257.0 ± 78.2* <0.001
Stage 1, min 58.2 ± 32.0 39.5 ± 37.9 48.2 ± 53.7 73.5 ± 59.8* 0.006
Stage 2, min 139.6 ± 71.8 103.2 ± 67.3 125.7 ± 69.6 70.9 ± 43.30* <0.001
Baseline SaO2, % 97.3 ± 0.96 95.5 ± 1.77 93.9 ± 3.07 92.0 ± 4.87
* <0.001
Lowest SaO2, % 91.3 ± 3.09 88.4 ± 3.82 81.3 ± 8.68
* 79.0 ± 8.87* <0.001
ESS 8.7 ± 4.6 8.9 ± 5.2 10.4 ± 5.9 11.6 ± 6.0* 0.029
AHI: apnea-hypopnea index; ESS: Epworth sleepiness scale
*p < 0.05 vs. control group, +p < 0.05 vs. mild OSAS group
Song et al. Clinical Hypertension  (2016) 22:1 Page 5 of 8
is a useful inflammatory marker because it reflects the in-
crease in platelet count, and decrease in lymphocyte count
in an inflammatory state [29]. In the present study, we se-
lected PLR as a potential inflammatory marker because it
is easily calculated using the results of routine peripheral
blood tests, and reflects systemic inflammation in OSAS
patients. In addition, PDW increases with changes in
platelet morphology and size, both of which occur in in-
flammatory states [16]. We hypothesized that both PLR
and PDW would linearly increase according to the severity
of OSAS. Both of these responses were demonstrated
in this study, and because RBC showed no significant
correlation with AHI, the correlation between PLR or
PDW and AHI may not simply a consequence of in-
creased blood viscosity in patients with OSAS. Moreover,
although the PLR and hs-CRP showed significant correl-
ation in our study, the useful inflammatory markers in
OSAS were platelet-related inflammatory markers, not hs-
CRP. In addition, inflammatory markers are also con-
nected to the development and/or progression of obesity,
type 2 diabetes mellitus, and hypertension. To explore the
independent role of PLR and PDW on the severity of
OSA, we performed multivariate logistic regression
analysis, which showed that PLR and PDW were
Fig. 3 The correlations between inflammatory markers and clinical factors of OSAS. a The platelet to lymphocyte ratio (PLR) was significantly
associated with the apnea-hypopnea index (AHI) (r = 0.417, p <0.001). b The platelet distribution width (PDW) was significantly correlated with
AHI (r = 0.227, p <0.001)
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independently associated with AHI after adjustment of
traditional CVD risk factors and obesity.
Another interesting finding from this study is that
OSAS patients with concurrent hypertension had signifi-
cantly higher PLR values than did those without hyper-
tension. The hypertension that occurs with OSAS may
be multifactorial in origin. Systemic inflammation likely
plays a major role in the development of hypertension in
OSAS. A previous study showed that OSAS patients
with hypertension had higher levels of inflammation and
insulin resistance than do those without hypertension
[30]. Since systemic inflammation plays an important
role in hypertension in OSAS, PLR may have a role in
the development of hypertension in OSAS patients. We
hypothesized that PLR, as a measurable biomarker of
systemic inflammation, may be independently associated
with hypertension in OSAS patients. Our results suggest
that PLR may be useful inflammatory biomarker associ-
ated with concurrent hypertension in OSAS, even after
adjusting for AHI. This finding suggests that inflamma-
tion and subsequent hypertension in OSAS are inde-
pendent of the severity of upper way obstruction.
This study has several limitations. Since this was a retro-
spective cohort study, the blood sampling and test param-
eters were not performed with identical methods. Any
variability may have influenced the value of the parameter.
In addition, PLR and PDW were based on single measure-
ments. It would be important to determine whether PLR
changes over time, and if it is a consistent predictor of
OSAS severity. Our study was also conducted with a rela-
tively small sample of patients that was likely insufficient
to demonstrate cardiovascular outcomes. In order to
achieve more statistical power and substantiate our find-
ings, larger randomized controlled trials are necessary.
Table 3 OSAS patient characteristics according to the presence of hypertension
Control (n = 61) OSAS without HTN (n = 168) OSAS with HTN (n = 61) ANOVA p
Age, years 44.0 ± 15.4 48.9 ± 13.0* 52.4 ± 11.4* 0.002
Male, n (%) 33 (54.1) 115 (68.5) 45 (73.8) 0.051
BMI, kg/m2 24.2 ± 4.4 26.0 ± 3.5* 26.6 ± 3.1* 0.001
SBP, mmHg 123.4 ± 13.7 125.7 ± 12.7 130.1 ± 13.6* 0.018
DBP, mmHg 78.4 ± 10.7 78.8 ± 9.0 82.4 ± 10.1* 0.031
Heart rate, /min 73.3 ± 10.3 74.4 ± 9.4 72.0 ± 9.2 0.177
Diabetes mellitus, n (%) 4 (6.5) 9 (5.4) 7 (11.5) 0.255
Dyslipidemia, n (%) 2 (3.3) 6 (3.6) 2 (3.3) 0.993
Smoking, n (%) 6 (9.8) 32 (19.0) 14 (23.0) 0.120
Total cholesterol, mg/dl 170.0 ± 38.2 186.1 ± 44.9 169.0 ± 38.6 0.082
TG, mg/dl 151.2 ± 80.3 157.5 ± 110.1 174.1 ± 128.3 0.716
FBS, mg/dl 101.5 ± 17.2 103.9 ± 33.7 109.9 ± 35.9 0.513
ESR, mm/hr 7.8 ± 11.6 16.4 ± 19.3 12.4 ± 11.2 0.095
hs CRP, mg/L 0.53 ± 1.32 1.02 ± 2.10 1.07 ± 1.61 0.427
PLR 99.5 ± 42.3 121.4 ± 55.5* 147.9 ± 61.8* <0.001
PDW, % 15.9 ± 1.12 16.37 ± 0.81* 16.44 ± 1.13* 0.002
AHI 1.91 ± 1.69 33.8 ± 30.1* 58.2 ± 68.3* <0.001
ESS 8.65 ± 4.64 10.1 ± 5.85* 12.4 ± 5.40* 0.009
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR: heart rate; TG: triglyceride; FBS: fasting blood sugar; ESR, erythrocyte
sedimentation rate; hs-CRP, highly sensitive C-reactive protein; PLR, platelet lymphocyte ratio; PDW, platelet volume distribution width; AHI, apnea-hypopnea
index; ESS, Epworth sleepiness scale; *p < 0.05 vs. control group
Table 4 Binary regression analysis of hypertension
Parameters Odd ratio (95 % CI) p-value Adjusted Odd ratio (95 % CI) p-value
Age, years 1.03 (1.01 to 1.05) 0.011 1.02 (0.99 to 1.05) 0.081
BMI, kg/m2 1.06 (0.99 to 1.14) 0.103 1.00 (0.90 to 1.10) 0.949
Male gender (%) 1.21 (0.67 to 2.18) 0.538 1.31 (0.57 to 2.84) 0.554
AHI ≥9.2 5.45 (2.38 to 12.48) <0.001 5.03(1.67 to 15.2) 0.004
PLR ≥159 3.37 (1.67 to 6.79) 0.001 2.81 (1.34 to 5.91) 0.006
CI, confidence intervals, BMI, body mass index; AHI, apnea-hypopnea index; PLR, platelet lymphocyte ratio
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Conclusion
In conclusion, this study demonstrates evidence of in-
flammation and platelet activation in OSAS. Therefore,
PLR and PDW may be relevant inflammatory markers of
OSAS severity. Furthermore, PLR may be a useful in-
flammatory biomarker associated with concurrent hyper-
tension in OSAS. Further, larger studies using PLR and
PDW are needed to assess the effectiveness of continu-
ous positive airway pressure therapy on OSAS.
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